Sensus Healthcare (NASDAQ:SRTS – Get Free Report) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Sensus Healthcare to announce earnings of ($0.1250) per share and revenue of $4.6010 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.
Sensus Healthcare (NASDAQ:SRTS – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%. The company had revenue of $3.39 million during the quarter, compared to analyst estimates of $5.32 million.
Sensus Healthcare Price Performance
Sensus Healthcare stock opened at $2.85 on Thursday. The business has a 50 day simple moving average of $2.95 and a 200-day simple moving average of $3.81. Sensus Healthcare has a 12 month low of $2.66 and a 12 month high of $5.92. The stock has a market capitalization of $46.91 million, a PE ratio of -6.06 and a beta of 1.09.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of brokerages have commented on SRTS. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Sensus Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $6.88.
Read Our Latest Stock Report on SRTS
Sensus Healthcare Company Profile
Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.
The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.
Read More
- Five stocks we like better than Sensus Healthcare
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
